
What are the pros and cons of bispecific antibodies for multiple myeloma?
Multiple Myeloma Hub
Comparing CARTY Cells and Bi-specific Antibodies in Multiple Myeloma Treatment
Speakers discuss the effectiveness and considerations of CARTY cells versus bi-specific antibodies for multiple myeloma patients, highlighting the evolving landscape of therapies and emphasizing the importance of individualized patient choices.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.